Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 May;10(5):1268-75.
doi: 10.1111/j.1600-6143.2010.03070.x. Epub 2010 Mar 19.

Virologic and clinical outcomes of hepatitis B virus infection in HIV-HBV coinfected transplant recipients

C S Coffin  1 , P G Stock, L M Dove, C L Berg, N N Nissen, M P Curry, M Ragni, F G Regenstein, K E Sherman, M E Roland, N A Terrault
Affiliations

Virologic and clinical outcomes of hepatitis B virus infection in HIV-HBV coinfected transplant recipients

C S Coffin et al. Am J Transplant. 2010 May.

Abstract

Liver transplantation (LT) is the treatment of choice for end-stage liver disease, but is controversial in patients with human immunodeficiency virus (HIV) infection. Using a prospective cohort of HIV-hepatitis B virus (HBV) coinfected patients transplanted between 2001-2007; outcomes including survival and HBV clinical recurrence were determined. Twenty-two coinfected patients underwent LT; 45% had detectable HBV DNA pre-LT and 72% were receiving anti-HBV drugs with efficacy against lamivudine-resistant HBV. Post-LT, all patients received hepatitis B immune globulin (HBIG) plus nucleos(t)ide analogues and remained HBsAg negative without clinical evidence of HBV recurrence, with a median follow-up 3.5 years. Low-level HBV viremia (median 108 IU/mL, range 9-789) was intermittently detected in 7/13 but not associated with HBsAg detection or ALT elevation. Compared with 20 HBV monoinfected patients on similar HBV prophylaxis and median follow-up of 4.0 years, patient and graft survival were similar: 100% versus 85% in HBV mono- versus coinfected patients (p = 0.08, log rank test). LT is effective for HIV-HBV coinfected patients with complications of cirrhosis, including those who are HBV DNA positive at the time of LT. Combination HBIG and antivirals is effective as prophylaxis with no clinical evidence of HBV recurrence but low-level HBV DNA is detectable in approximately 50% of recipients.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Cumulative patient survival, comparing HBV-HIV coinfected (N=22) and HBV monoinfected (N=20) transplant recipients. No significant differences were observed in patient survival between groups (p=0.09, log rank test)
See this image and copyright information in PMC

References

    1. Samuel D, Weber R, Stock P, Duclos-Vallee JC, Terrault N. Are HIV-infected patients candidates for liver transplantation? J Hepatol. 2008;48(5):697–707. - PubMed
    1. Soriano V, Barreiro P, Nunez M. Management of chronic hepatitis B and C in HIV-coinfected patients. J Antimicrob Chemother. 2006;57(5):815–818. - PubMed
    1. Soriano V, Puoti M, Bonacini M, Brook G, Cargnel A, Rockstroh J, et al. Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel. AIDS. 2005;19(3):221–240. - PubMed
    1. Roland ME, Stock PG. Review of solid-organ transplantation in HIV-infected patients. Transplantation. 2003;75(4):425–429. - PubMed
    1. Stock PG, Roland ME, Carlson L, Freise CE, Roberts JP, Hirose R, et al. Kidney and liver transplantation in human immunodeficiency virus-infected patients: a pilot safety and efficacy study. Transplantation. 2003;76(2):370–375. - PubMed

Publication types

MeSH terms